^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Glioma
    Drug:disufenton sodium (OKN-007) (Oxygen radical scavenger)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    PRNewswire
    Title:

    Oblato Announces Fast Track Designation of OKN-007 for Diffuse Intrinsic Pontine Glioma from the FDA

    Published date:
    03/03/2021
    Excerpt:
    ...Oblato, Inc. (the Company), a wholly owned U.S. subsidiary of the Korean biotech company GtreeBNT Co., Ltd., announces that the FDA granted Fast Track Designation of OKN-007, the proprietary drug for Diffuse Intrinsic Pontine Glioma (DIPG).